FdaApplication
NDA 210951
Identifiers
- fda_app_no: NDA210951
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN BIOTECH INC |
| application_type | NDA |
| approval_date | 2018-02-14 |
Revenue by product
ERLEADA
| Period | Revenue |
|---|---|
| Q2 2026 | $995.0M |
| Q1 2026 | $949.0M |
| Q3 2025 | $936.0M |
| Q2 2025 | $908.0M |
| Q1 2025 | $771.0M |
| Q3 2024 | $790.0M |
| Q2 2024 | $736.0M |
| Q1 2024 | $689.0M |
| Q3 2023 | $631.0M |
| Q2 2023 | $567.0M |
| Q1 2023 | $542.0M |
| Q3 2022 | $490.0M |
| Q2 2022 | $450.0M |
| Q1 2022 | $400.0M |
| Q3 2021 | $344.0M |
| Q2 2021 | $302.0M |
| Q1 2021 | $261.0M |
| Q3 2020 | $206.0M |
| Q2 2020 | $170.0M |
| Q1 2020 | $143.0M |
| Q3 2019 | $86.0M |
| Q2 2019 | $69.0M |
| Q1 2019 | $61.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ERLEADA | APALUTAMIDE | 60MG | TABLET;ORAL |
| ERLEADA | APALUTAMIDE | 240MG | TABLET;ORAL |
2 products